Remibrutinib cleared for chronic spontaneous urticaria
- Sponsor
- Novartis Pharmaceuticals UK Limited $NVS
- Drug
- Rhapsido · remibrutinib
- Indication
- chronic spontaneous urticaria inadequately controlled by antihistamines
MHRA approves remibrutinib (Rhapsido) for adults with chronic spontaneous urticaria inadequately controlled by antihistamines.
What this means
Rhapsido is a daily pill that calms an overactive immune system to reduce the hives and itching of chronic spontaneous urticaria. The UK's medicines regulator has now approved it for adults whose symptoms aren't controlled by standard antihistamines. This provides a new oral treatment option for patients struggling with this unpredictable skin condition.
From the source
Press release
MHRA approves remibrutinib for adults with chronic spontaneous urticaria
As with any medicinal product, the MHRA will keep the safety and effectiveness of remibrutinib under close review.
From: Medicines and Healthcare products Regulatory Agency
Published: 6 August 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved remibrutinib (Rhapsido) 25 mg film-coated tablets for the treatment of adults with chronic spontaneous urticaria (CSU) whose symptoms are not adequately controlled by antihistamines. Remibrutinib was approved through the International Recognition Procedure (IRP) Route B.
Chronic spontaneous urticaria is a long-term condition that causes recurrent hives, itching and swelling. In people with CSU, the immune system can become overactive. Remibrutinib works by blocking Bruton’s tyrosine kinase (BTK), helping to reduce inflammation and make symptoms less frequent and less severe.
The approval follows assessment of evidence from two main clinical studies involving 925 adults with chronic spontaneous urticaria for whom H1 antihistamine treatment did not work well enough. Patients treated with remibrutinib experienced significantly greater reductions in itch and hive symptoms compared with placebo.
Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:
The approval of remibrutinib provides a new treatment option for adults living with chronic spontaneous urticaria whose symptoms are not adequately controlled by antihistamines.
As with all licensed medicines, we will continue to monitor its safety through the UK Yellow Card scheme and encourage patients and healthcare professionals to report any suspected side effects.
Notes to editors:
• This marketing authorisation was granted to Novartis Pharmaceuticals UK Limited on 5 August 2026.
• This product was submitted and approved via the International Recognition Procedure (IRP) Route B.
• More information can be found in the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) available on the MHRA website.
• Healthcare professionals and patients are encouraged to report suspected adverse reactions via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk.
Updates to this page
Published 6 August 2026
Reproduced from MHRA News · view original · public domain or open-licensed government work
Drug Watch — recent news on Rhapsido
- Could Remibrutinib Become the Next $9 Billion Drug for Novartis? - Yahoo Finance
- Novartis’ board faces investor scrutiny after M&A misfires and R&D flops - BioSpace
- Potential Pill for Peanut, Milk, Egg Allergies Enters Phase 3 Trial - Allergic Living
- Novartis’ Rhapsido adds oral option for chronic hives, but cost remains hurdle - Korea Biomedical Review
- BofA Sees Remibrutinib Detailed Data as Next Major Catalyst to Offset Novartis Pipeline Misses; Buy Rating Kept - marketscreener.com
Sponsor Watch — recent news on Novartis Pharmaceuticals UK Limited
- What does the EU have that the U.S. does not?
- Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform
- Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
- Edison (BIT:EDNR) Shares Dropped, So What Is Driving Attention Now?
- Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years